Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Metabolomics meets inflammatory diseases
February 2017
SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.—Metabolon Inc. and InnVentis Inc. have united in an agreement that will apply metabolomics in studying individuals with chronic inflammatory diseases, beginning with joint precision medicines studies into rheumatoid arthritis. InnVentis’ platform unites data with cutting-edge algorithms to provide actionable insights through the sourcing of multi-omics and clinical analytics as well as machine learning and careful sample/data collection control. No financial details were released.
 
“We’re working with InnVentis to expand the knowledge we can apply toward chronic inflammatory diseases, starting with studies of rheumatoid arthritis,” Dr. John Ryals, CEO of Metabolon, commented in a statement. “Our goal is to use our proprietary technology in conjunction with InnVentis’s platform to provide a more accurate health assessment of patients, as well as clinically useful information. Metabolomics may help answer key biological questions about these complex disorders and improve personalized treatment.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.